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High expression of PKC-MAPK pathway mRNAs correlates
with glomerular lesions in human diabetic nephropathy.
Background. Activation of protein kinase C (PKC) is a ma-
jor signaling pathway for transforming growth factor (TGF)−b
to induce extracellular matrix (ECM) production in diabetic
nephropathy (DN). PKC also activates mitogen-activated pro-
tein kinase (MAPK), which is called the PKC-MAPK pathway.
The PKC-MAPK pathway is probably responsible for PKC-
related abnormalities in diabetic glomeruli. To confirm the in-
volvement of this pathway, we determined the localization and
expression of mRNAs in glomeruli by in situ hybridization
method.
Methods. In the present study, we examined expression of
PKCb1, MAPK/ERK kinase (MEK) 1, MEK2, extracellular
signal-regulated protein kinase (ERK) 1, ERK2, and TGF-b1
mRNAs using renal tissue samples from kidneys affected by
DN (N = 21) and from normal human kidney (NHK; N = 6).
We also performed an immunohistochemical study using anti-
phosphorylated MEK1/2 (P-MEK) and ERK1/2 (P-ERK) anti-
bodies. The glomerular severity of DN was classified into three
groups according to mesangial expansion: D1 (N = 4), D2 (N =
13), and D3 (N = 4). We analyzed differences and correlations
between variables.
Results. In the glomeruli, the number of cells that stained
for these mRNAs in DN was significantly higher than in NHK.
The expression of PKC-MAPK pathway mRNAs tended to be
inversely proportional to the degree of mesangial expansion.
The P-MEK and P-ERK signal intensity were parallel to its
mRNA expression pattern. Furthermore, there were significant
correlations among the P-MEK, P-ERK signal intensity, PKCb1
mRNA expression.
Conclusion. Our results suggest that high expression of PKC-
MAPK pathway mRNAs plays an important role in the devel-
opment and/or progression of early tissue damage in DN.
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forming growth factor-b , diabetic nephropathy, in situ hybridization.
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Diabetic nephropathy (DN) is a major chronic com-
plication of diabetes mellitus and an important cause of
increased morbidity and mortality in patients with dia-
betes mellitus. Elucidation of the mechanisms involved
in its pathogenesis and/or progression is therefore very
important. Several pathogenic mechanisms have been
proposed for diabetic glomerular damage. Diacylglycerol
(DAG)-induced activation of protein kinase C (PKC)
contributes significantly to the pathogenesis of DN [1–4].
We previously reported that PKCa and/or b1 might play
an important role in the development and progression
of glomerulosclerosis in DN [5]. PKC is known to acti-
vate mitogen-activated protein kinase (MAPK) through
activating MAPK kinase (MAPKK). This serial cascade,
PKC-MAPKK-MAPK, is variously known as the PKC-
MAPK pathway, PKC-extracellular signal-regulated ki-
nase (ERK) pathway, MAPK/ERK kinase (MEK)-ERK
pathway, or MAPK cascade [6–13]. ERK, which is one
of the MAPKs, is an important kinase in the intracellu-
lar signal transduction system leading to cell proliferation
and extracellular matrix protein synthesis [14–16], and it
is well known that the direct upstream activator of ERK
is a dual-specificity protein kinase, MEK [17].
Activation of the PKC-MAPK pathway induces en-
hanced extracellular matrix protein and transforming
growth factor (TGF)-b expression, suggesting that PKC-
induced activation of this pathway might be responsi-
ble for PKC-related abnormalities in diabetic glomeruli,
leading to the development of DN [3, 4, 6]. Based on
recent studies that investigated the role of PKCs and
MAPKs in the development and/or progression of DN,
it is plausible that PKCb1 is the primary activator of
the PKC-MAPK pathway, leading to overexpression of
TGF-b1. The existence or activation of the PKC-MAPK
pathway has been well established by studies at the pro-
tein level, that is, by studying increased serine/threonine
phosphorylation under high glucose conditions. How-
ever, whether the expression of PKC-MAPK pathway
mRNAs is higher in human DN tissues is unknown. The
present study was designed to determine the mRNA
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expression in this pathway. Specifically, we studied the
distribution patterns and expression levels of PKCb1,
MEK1, MEK2, ERK1, ERK2, and TGF-b1 mRNAs in
glomeruli by in situ hybridization using renal tissue sam-
ples from kidneys affected by DN and also from normal
human kidney (NHK). We also performed an immuno-
histochemical study using anti-phosphorylated MEK1/2
and ERK1/2 antibodies to elucidate the relationship be-




Open renal biopsy tissues were obtained from 21 pa-
tients with DN. The presence of DN was confirmed by
pathologic evaluation of renal biopsy specimens using
light microscopy, immunofluorescence staining, and elec-
tron microscopy. We also examined control samples ob-
tained from six subjects, using uninvolved portions of
surgically removed kidneys afflicted with malignancies.
After resection, samples for in situ hybridization study
were embedded in OCT compound (Tissue Tek; Miles,
Elkhart, IN, USA) and stored at −70◦C until use. Tissue
for glomerular severity grading were embedded in paraf-
fin, cut in 4 lm sections, and stained with periodic-acid
Shiff (PAS). The severity of glomerular mesangial expan-
sion was graded on a four-point scale from D1 through D4
using the criteria of Gellman et al: D1 (N = 4), D2 (N =
13), D3 (N = 4); there were no D4 patients in our present
patients (Fig. 2) [18]. The Human Research Committee
of the Tokai University School of Medicine approved the
study, and informed consent for open renal biopsy and in
situ hybridization studies was obtained from each patient
before the commencement of the study [19]. The follow-
ing clinical parameters were documented at the time of
open renal biopsy: gender, age, serum creatinine, total
protein, fasting plasma glucose, HbA1c, urinary protein,
and creatinine clearance (Tables 1 and 2).
In situ hybridization
Nucleotide sequences of human PKCb1, MEK1,
MEK2, ERK1, ERK2, and TGF-b1 cDNA were used
as probes (Table 3). One hundred pmol of the oligonu-
cleotide probes were labeled using a digoxigenin (DIG)
oligonucleotide tailing kit according to the standard pro-
tocol (Boehringer Mannheim, Mannheim, Germany).
Free DIG was removed by ethanol precipitation and
dissolved in diethylpyrocarbonate-treated water. In situ
hybridization was performed according to the modified
technique developed in our laboratory [20, 21]. Briefly,
fresh kidney biopsy tissues were embedded in OCT com-
pound and stored at −70◦C until use. Specimens were
cut to a thickness of 4 lm, and sections were fixed
in 4% paraformaldehyde in phosphate-buffered saline
(PBS) and then deproteinized with HCl and digested
with proteinase K (Sigma Chemical, St. Louis, MO,
USA). The specimens were prehybridized in a hybridiza-
tion buffer, drained, and then hybridized overnight with
a DIG-labeled oligonucleotide probe in the hybridiza-
tion buffer. After hybridization, the DIG-labeled probe
was visualized by immunohistochemical staining using
a mouse monoclonal anti-DIG antibody (Boehringer
Mannheim), horseradish peroxidase (HRP)-conjugated
rabbit antimouse IgG antibody (Dako, Glostrup,
Denmark), and HRP-conjugated swine antirabbit IgG
antibody (Dako). Color was developed with diaminoben-
zidine tetrahydrochloride in 0.05 mol/L Tris-HCl, pH 7.6,
and 0.03% H2O2. Sections were briefly counterstained
with hematoxylin, rinsed, dehydrated, cleared in xylene,
and mounted. To evaluate the specificity of the signals,
two types of control experiments were carried out as de-
scribed previously [20, 21]. First, a competitive study was
performed by adding a 100-fold excess of homologous or
unrelated, unlabeled oligonucleotides to the hybridiza-
tion buffer together with the antisense probe. Second,
pretreatment with RNase was performed after proteinase
K digestion, and thereafter, sections were prehybridized
and hybridized.
Immunohistochemistry
After fixation, kidneys were embedded in paraffin. Im-
munohistochemical staining was performed on sections
4 lm thick using the ABC immunoperoxidase method.
The antibodies for phospho-MEK1/2 (P-MEK) and
phospho-p44/p42 MAPK (P-ERK) were purchased from
Cell Signaling (Beverly, MA, USA). The Elite ABC kits
were purchased from Vector Laboratories (Birmingham,
CA, USA). Paraffin sections were deparafffinized and re-
hydrated. Endogenous peroxidase activity was quenched
by incubating sections in 1% H2O2 for 10 minutes. To
unmask antigens, slides were boiled at 100◦C for 10 min-
utes in 0.01 mol/L sodium citrate buffer (pH 6.0). Sections
were treated with 5% normal goat serum before incuba-
tion with primary antibodies overnight at 4◦C. Negative
controls were treated with 5% normal goat serum without
the primary antibodies. Signals were processed according
to the supplied protocol (Elite ABC kit).
Statistical analysis
Data are expressed as mean ± SD. To quantify the
expression of PKCb1, MEK1, MEK2, ERK1, ERK2,
and TGF-b1 mRNAs, we enumerated the total nu-
clei and the subpopulation of nuclei with surround-
ing mRNA-positive cytoplasm in at least 10 randomly
selected cross-sections of glomeruli. Quantification of
expression of these mRNAs was performed by three inde-
pendent investigators who were blinded to the results of
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Fig. 1. Light microscopic findings in glomeruli from representative patients with diabetic nephropathy (DN) by periodic acid-Schiff (PAS) staining.
The glomerular severity of DN was classified into three groups according to mesangial expansion [(A) D1, ×100; (B) D2, ×100; (C) D3, ×100).
Fig. 4. Detection of P-MEK and P-ERK protein in representative tissues of DN of various pathologic grades (A to H). Expression of P-MEK in
D1, D2, and D3 [(A) D1, ×100; (B) D2, ×100; (C) D3, ×100]. Expression of P-ERK are also presented [(E) D1, ×100; (F) D2, ×100; (G) D3,
×100]. The specificity of signals detected by immunohistochemistry was confirmed by negative controls and were treated with 5% normal goat
serum without the primary antibodies [(D) D1, ×100; (H) D1, ×100].
Table 1. Clinical parameters at the time of renal biopsy in DN
and NHK
DN NHK P value
Gender M/F 17/4 3/3 NS
Age years 42 ± 12 58 ± 8 <0.05
Serum creatinine mg/dL 0.95 ± 0.58 0.77 ± 0.11 NS
Total protein g/dL 6.3 ± 1.0 6.5 ± 0.4 NS
Fasting plasma glucose mg/dL 158 ± 74 92 ± 8 <0.05
HbA1c % 9.2 ± 2.8 ND ND
Urinary protein g/day 1.23 ± 2.30 0.02 ± 0.01 <0.05
Creatinine clearance mL/min 98.4 ± 23.9 89.0 ± 2.6 NS
Abbreviations are: DN, diabetic nephropathy; NHK, normal human kidney;
NS, not significant; ND, not done. Data are expressed as mean ± SD.
histopathologic classification. Results were expressed as
the percentage of total glomerular cells that were mRNA-
positive. We also evaluated the immunohistochemical
staining intensity in randomly selected cross-sections of
glomeruli. Intensity of staining with antibody to P-MEK
and P-ERK was graded using scores as follows: +1 = very
weak; +2 = weak; +3 = moderate; +4 = strong. Differ-
ences between groups were analyzed for statistical signif-
icance using Kruskal-Wallis test or the Mann-Whitney U
test. Spearman rank correlation was applied to test the




In situ hybridization identified cells positive for ERK1
mRNA in the glomeruli of NHK and kidneys with DN
(Figs. 2 and 3). In situ hybridization followed by PAS
staining revealed ERK1 mRNA in glomerular resident
cells, predominantly glomerular mesangial and epithelial
cells, and to a lesser extent in cells of Bowman’s cap-
sule (Fig. 2A to C). Cells staining positively for PKCb1,
MEK1, MEK2, ERK2, and TGF-b1 mRNA were also ob-
served among glomerular mesangial and epithelial cells
(data not shown). The specificity of all mRNA signals
detected by in situ hybridization was confirmed by two
control studies. In a competitive experiment, the sig-
nals disappeared when a 100-fold excess of unlabeled
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Table 2. Clinical parameters at the time of renal biopsy in the four groups
D1 D2 D3 NHK P value
Gender M/F 3/1 10/3 3/1 3/3 NS
Age years 39 ± 9 41 ± 13 49 ± 13 58 ± 8 NS
Serum creatinine mg/dL 0.70 ± 0.18 0.81 ± 0.12 1.75 ± 1.12a 0.77 ± 0.11 <0.05
Total protein g/dL 6.4 ± 0.4 6.6 ± 0.9 5.3 ± 0.5a 6.5 ± 0.4 <0.05
Fasting plasma glucose 177 ± 142 168 ± 61 111 ± 146 92 ± 8 NS
mg/dL
HbA1c % 9.5 ± 4.0 9.1 ± 2.1 9.0 ± 3.8 ND NS
Urinary protein g/day 0.21 ± 0.18 0.61 ± 0.93b 4.77 ± 3.84a 0.02 ± 0.01 <0.05
Creatinine clearance 102.5 ± 8.2 89.6 ± 24.4 67.0 ± 19.3c 89.0 ± 2.6 <0.05
mL/min
Abbreviations are: DN, diabetic nephropathy; NHK, normal human kidney; NS, and significant; ND, not done. Data are expressed as mean ± SD.
aP < 0.05 vs. D1, D2, and NHK; bP < 0.05 vs. D3 and NHK; cP < 0.05 vs. D1.









homologous oligonucleotide was added to the standard
hybridization mixture containing labeled probe (Fig. 2D
to E). Furthermore, pretreatment of tissue with RNase
before hybridization diminished the signals (data not
shown).
Figure 3 shows PKCb1, MEK1, MEK2, ERK2, and
TGF-b1 mRNA expression in glomeruli according to the
severity of DN. Glomerular expression of all mRNAs
were markedly increased in D1 and D2 compared with
D3 (Fig. 3). Table 4 shows the percentage of glomerular
cells positive for PKCb1, MEK1, MEK2, ERK1, ERK2,
and TGF-b1 mRNAs in DN and NHK. The percentages
of cells positive for these mRNAs in DN were signifi-
cantly higher than NHK. Furthermore, the percentages
of cells positive for all mRNAs were significantly differ-
ence among the four groups (Kruskall-Wallis test P <
0.05 or <0.01). Moreover, positive percent of D1 and D2
were significantly higher than in D3 or NHK with respect
to PKCb1, MEK1, MEK2, ERK1, and ERK2, except for
TGF-b1 mRNA (Table 5).
Immunohistochemistry
To examine the relationship between MEK, ERK
mRNA expression, and MEK, ERK activation we per-
formed an immunohistochemical study using phospho-
specific antibodies in paraffin-embedded tissues. P-MEK
and P-ERK protein were demonstrated in glomeruli of
the kidneys of all groups. Figure 4 shows nuclear local-
ization in glomeruli according to the severity of DN. The
specificity of signals detected by immunohistochemistry
was confirmed by negative controls and were treated with
5% normal goat serum without the primary antibodies.
The intensity of P-MEK and P-ERK antibodies tended
to be inversely proportional to the degree of mesangial
expansion (Table 6).
Correlation between MAPK phosphorylation and
mRNA expression
To elucidate involvement of the PKC-MAPK pathway
for stimulation of TGF-b1, we analyzed the correlations
between signal intensity of P-MEK, P-ERK intensity,
and mRNA expression of PKCb1, TGF-b1. There were
significant correlations between P-MEK, P-ERK inten-
sity, and PKCb1 mRNA expression. However, TGF-b1
mRNA expression was not correlated with both P-MEK
and P-ERK (Table 7).
DISCUSSION
PKC is a key enzyme in signaling pathways that reg-
ulates cell growth and function [22–30]. At least 11
isoforms of PKC have been identified in mammalian tis-
sues, and these are divided into three groups: classic PKC
(cPKC), new PKC (nPKC), and atypical PKC (aPKC) [7,
31]. The cPKC group comprises a, b1, b2, and c isoforms,
the nPKC group comprises d, e, h, g, and l isoforms, and
the aPKC isoforms are n and k.Ca2+, phosphatidylser-
ine, and DAG activates the cPKC isoforms. CPCK iso-
forms, especially PKCa and b1, have been reported to be
involved in the progression of DN [4, 7, 32]. We previ-
ously reported high expression of PKCa and b1 mRNA
in renal tissue samples from patients with DN, and our
results suggested an important role for PKCa and b in
the development and progression of DN [5]. It is well
known that activated PKC triggers the MAPK cascade
[33]. Recently, the importance of MAPK in diabetic com-
plications has been reviewed [34, 35]. From some recent
reports that studied the role of PKCs and MAPKs in the
development and/or progression of diabetic nephropa-
thy, we supposed that PKC1 might activate MEK and
ERK, and lead to overexpression of TGF-b1 [6, 32, 36,
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Fig. 2. Cells positive for extracellular signal-regulated protein kinase
(ERK1) mRNA in the glomeruli of normal human kidney (NHK) (A to
D). In situ hybridization followed by period-acid Schiff (PAS) staining
identified ERK1 mRNA in glomerular resident cells, mainly glomerular
mesangial (arrow) and epithelial cells (arrowheads) [(A) ERK1, ×200;
(B) ERK1, ×200]. The double arrow indicates an epithelial cell of Bow-
man’s capsule [(C) ERK1, ×200]. Figure 2D represents typical mRNA
positive signals in glomeruli [(D) NHK, ×100]. In a competitive ex-
periment, the signals disappeared when a 100-fold excess of unlabeled
homologous oligonucleotide was added to the standard hybridization
mixture containing labeled probe [(E) NHK, ×100].
37, 39]. Activation of the PKC-MAPK pathway has been
well established by studies at the protein level, that is, by
detecting increased serine/threonine phosphorylation in
high glucose conditions. However, whether the expres-
sion of mRNAs of the PKC-MAPK pathway is higher in
tissues of human DN is still not fully understood. Thus, in
this study we examined the expression and distribution
of PKCb1, MEK1, MEK2, ERK1, ERK2, and TGF-b1
mRNAs. The most important aim of this study was to
determine whether the PKC-MAPK pathway was acti-
vated with increased mRNA expression in human DN.
Thus, we studied the expression and localization of these
mRNAs in human kidney tissues and assessed the differ-
ences between NHK and DN tissues. Moreover, we inves-
tigated the correlation between expression levels of these
mRNAs and glomerular damage of DN.
To our knowledge, the present study is the first report
to demonstrate the expression of PKC-MAPK pathway
mRNAs in human renal tissues with DN. The signals for
these mRNAs were present among glomerular resident
cells, predominantly glomerular mesangial and epithelial
cells, and to a lesser extent in cells of Bowman’s capsule.
The activation of PKC and ERK in glomerular podocytes
under high glucose conditions was observed by using a
Fig. 3. Detection of all mRNAs in representative tissues of DN of var-
ious pathologic grades (A to R). Expression of PKC b1 mRNA in D1,
D2, and D3 [(A) D1, ×100; (B) D2, ×100; (C) D3, ×100]. Expression of
MEK1, MEK2, ERK1, ERK2, and TGF-b1 mRNAs are also presented
[(D to F) MEK1, ×100; (G to I) MEK2, ×100; (J to L) ERK1, ×100;
(M to O) ERK2, ×100; (P to R) TGF-b1, ×100].
differentiated mouse podocyte cell line [38]. Isono et al
[39] confirmed that ERK was activated in mesangial cells
cultured in high glucose and in the glomeruli of diabetic
rats. On the other hand, in bovine pulmonary artery en-
dothelial cells, ERK activity was not increased by glu-
cose [40]. Considered together, these results suggest that
PKC, MEK, and ERK may be synthesized and activated
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Table 4. Comparison of mRNA expression between DN and NHK
DN NHK P value
PKC b1 15.6 ± 3.9 8.9 ± 1.3 <0.05
MEK1 13.5 ± 2.8 6.3 ± 1.5 <0.01
MEK2 12.8 ± 2.4 8.0 ± 1.4 <0.01
ERK1 20.8 ± 6.3 13.2 ± 1.7 <0.05
ERK2 19.1 ± 74 13.2 ± 1.6 <0.05
TGF-b1 18.5 ± 6.0 11.5 ± 0.9 <0.05
Abbreviations are: DN, diabetic nephropathy; NHK, normal human kidney;
NS, not significant; ND, not done. Data are expressed as mean ± SD.
Table 5. Comparison of mRNA expression in the four groups
D1 D2 D3 NHK P value
PKC b1 18.1 ± 1.4a 16.6 ± 3.4a 10.9 ± 2.2 8.9 ± 1.3 <0.01
MEK1 13.4 ± 1.4a 14.3 ± 2.7a 10.4 ± 1.1 6.3 ± 1.5 <0.01
MEK2 13.6 ± 1.2a 13.3 ± 2.5b 10.5 ± 1.2 8.0 ± 1.4 <0.01
ERK1 24.3 ± 1.7a 22.7 ± 5.1a 12.6 ± 4.7 14.4 ± 4.7 <0.01
ERK2 21.5 ± 2.4a 20.5 ± 3.4a 13.7 ± 4.3 13.2 ± 1.6 <0.01
TGF-b1 17.3 ± 5.9 18.9 ± 6.4 14.1 ± 3.4 11.5 ± 0.9 <0.05
Abbreviations are: NHK, normal human kidney. Data are expressed as
mean ± SD.
aP < 0.05 vs. D3 and NHK; bP < 0.05 vs. NHK.
Table 6. Comparison of phosphorylated MEK an ERK intensity in
DN groups
D1 D2 D3 P value
P-MEK 3.5 ± 0.6a 2.0 ± 0.7b 1.3 ± 0.5 <0.01
P-ERK 3.3 ± 0.5a 2.1 ± 0.9b 1.3 ± 0.5 <0.01
P-MEK, phosphrylated-MEK; P-ERK, phosphorylated ERK.
aP < 0.05 vs. D2 and D3; bP < 0.05 vs. D3.
predominantly by glomerular epithelial and mesangial
cells in the glomeruli. Recent evidence suggests that the
MAPKs, such as ERK1 and ERK2, play an important
role in the intracellular signal transduction system lead-
ing to various cellular functions [14, 15]. Haneda et al [6]
have shown that ERK is activated in mesangial cells cul-
tured under high glucose conditions, and that this activa-
tion is dependent on activation of PKC. ERK1 and ERK2
are activated by immediate upstream kinases, MEK1 and
MEK2. This serial pathway, called the PKC-MAPK path-
way, appears to be conserved during evolution and thus
might play an essential role in diverse intracellular sig-
naling processes, from yeasts to vertebrates [41]. We as-
sessed the percentages of glomerular cells positive for
mRNAs that are expressed in the PKC-MAPK pathway.
In glomeruli, the numbers of cells positive for PKCb1,
MEK1, MEK2, ERK1, ERK2, and TGF-b1 mRNAs in
kidney tissues with DN were significantly increased com-
pared with NHK. Our immunohitochemical study us-
ing phosphospecific antibodies revealed that P-MEK and
P-ERK intensity were parallel to MEK and ERK mRNA
expression pattern. These results suggest that the PKC-
MAPK pathway might be activated, with increasing lev-
els of mRNA expression, in human DN tissue, as well
Table 7. Correlation between phosphorylated MEK, ERK signal
intensity, and PKC b1, TGF-b1 mRNA expression
PKC b1 TGF-b1
P-MEK r = 0.625a r = 0.365
P-ERK r = 0.525a r = 0.259
P-MEK, phosphrylated MEK; P-ERK, phosphorylated ERK.
aP < 0.05.
as in experimental animal models or cultured cells under
high glucose conditions. In addition, P-MEK and P-ERK
intensities in glomeruli were significantly correlated with
the percentages of cells positive for PKCb1 (Table 7). This
suggests the existence of a serial pathway from PKCb1 to
MEK and ERK, that is, the PKC-MAPK pathway, and it
might be activated under high glucose conditions. In other
words, we confirmed the involvement of the PKC-MAPK
pathway in response to diabetic conditions in human dia-
betic kidney. Moreover, the PKC-MAPK pathway might
be implicated in the glomerular lesions of DN. Recent
data also suggest that seemingly disparate factors that
are thought to play a role in initiating DN all converge
to activate the TGF-b system in the kidney. In our study,
the percentages of glomerular cells positive for TGF-b1
mRNA were significantly increased in DN compared with
NHK. These results are in agreement with those of pre-
vious studies that described a tight relationship between
over-expression of TGF-b1 and development and/or pro-
gression of glomerular diseases [42, 43]. On the other
hand, the percentages of glomerular cells positive for
TGF-b1 mRNA were not significantly correlated with
P-MEK and P-ERK intensity. From our results, we feel
a strong similarity between TGF-b1 mRNA expression
pattern and the pattern of other PKC and MAPK mRNA,
and we assume that activation of PKC-MAPK pathway
in glomeruli may be responsible for high expression of
TGF-b1. A number of studies have demonstrated that in-
hibition of the PKC b isoform or PKC-MAPK pathway
could prevent the hyperglycemia-induced induction of
TGF-b1 [32, 37, 39]. Various reasons for this disparity in
findings can be considered. One is the difference between
human kidney tissues and animal models and/or cultural
cells. In addition, the experimental environment was dif-
ferent, that is, diabetes versus a hyperglycemia state. This
disparity also invokes the existence of triggers that can in-
duce overexpression of TGF-b1, distinct from the PKC-
MAPK pathway. Various factors are known to stimulate
the TGF-b system in the kidney, including intrarenal an-
giotensin II activation, oxidative stress, serum, or matrix
proteins that are modified by early and advanced glyca-
tion adducts, and activation of the polyol and glucosamine
pathways [44–50]. There may be a possibility that several
stimulations besides high glucose listed above accelerate
the expression of TGF-b1. Therefore, further studies are
necessary to identify the precise mechanisms of regula-
tion of TGF-b1 mRNA in human kidney.
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There have been no previous reports evaluating PKC-
MAPK pathway mRNA expression in various tissues
damaged in DN. To our knowledge, this is the first re-
port to demonstrate alterations in expression of these
mRNAs concomitant with deteriorating histopathologic
changes in renal tissues affected by DN. Our results re-
vealed that PKC-MAPK pathway mRNA expression was
significantly greater in D1 and D2 than in D3, and that the
expression tended to decrease with the degree of mesan-
gial expansion. These results indicate that PKC-MAPK
pathway mRNA expression is markedly increased in the
early stages of tissue damage, strongly suggesting that el-
evated expression of these mRNAs plays an important
role in the development and/or progression of early tis-
sue damage in DN. Considered together, our findings sug-
gest that up-regulation of PKC b1 may be accompanied
by high expression of ERK and MEK mRNA in the early
stage tissues of DN. Therefore, these results implicate the
PKC-MAPK pathway as an important component of the
mechanism of glomerular abnormalities in early DN.
CONCLUSION
We used human renal tissue samples from patients
with DN to demonstrate PKC b1, MEK1, MEK2, ERK1,
ERK2, and TGF-b1 mRNA expression by DIG-labeled
in situ hybridization in glomerular mesangial and epithe-
lial cells, and in cells of Bowman’s capsule. Expression
of these mRNAs varied with the progression of mesan-
gial expansion. Our results suggest that the PKC-MAPK
pathway may play an important role in the development
and progression of glomerulosclerosis in DN.
ACKNOWLEDGMENTS
This work was supported in part by grants from the Japan Foundation
for Aging and Health.
Reprint requests to Daisuke Suzuki, M.D., Ph.D., Division of
Nephrology and Metabolism, Department of Internal Medicine, Tokai
University School of Medicine, Isehara, Kanagawa 259–1193, Japan.
E-mail: daisuke@is.icc.u-tokai.ac.jp
REFERENCES
1. CRAVEN PA, DAVIDSON CM, DERUBERTIS FR: Increase in diacylglyc-
erol mass in isolated glomeruli by glucose from de novo synthesis
of glycerolipids. Diabetes 39:667–674, 1990
2. WILLIAMS B, SCHRIER RW: Glucose-induced protein kinase C ac-
tivity regulates arachidonic acid release and eicosanoid production
by cultured glomerular mesangial cells. J Clin Invest 92: 2889–2896,
1993
3. CRAVEN PA, DERUBERTIS FR: Protein kinase C is activated in
glomeruli from streptozotocin diabetic rats: Possible mediation by
glucose. J Clin Invest 83:1667–1675, 1989
4. KIKKAWA R, HANEDA M, UZU T, et al: Translocation of protein kinase
C a and n in rat glomerular mesangial cells cultured under high
glucose conditions. Diabetologia 37:838–841, 1994
5. TOYODA M, SUZUKI D, ZHANG SY, et al: In-situ hybridization studies
of protein kinase C a and b I isoforms in human diabetic nephropa-
thy. Clin Exp Nephrol 5:250–256, 2001
6. HANEDA M, ARAKI S, TOGAWA M, et al: Mitogen-activated protein
kinase cascade is activated in glomeruli of diabetic rats and glomeru-
lar mesangial cells cultured under high glucose conditions. Diabetes
46:847–853, 1997
7. KOYA D, KING GL: Protein kinase C activation and the development
of diabetic complications. Diabetes 47:859–866, 1998
8. XIAO ZL, ANDRADA MJ, BIANCANI P, et al: Reactive oxygen species
(H(2)O(2)): Effects on the gallbladder muscle of guinea pigs. Am J
Physiol Gastrointest Liver Physiol 282:G300–G306, 2002
9. ALETSEE C, BRORS D, PALACIOS S, et al: The effects of laminin-1 on
spiral ganglion neurons are dependent on the MEK/ERK signaling
pathway and are partially independent of Ras. Hear Res 164:1–11,
2002
10. UEDA Y, HIRAI S, OSADA S, et al: Protein kinase C activates the
MEK-ERK pathway in a manner independent of Ras and depen-
dent on Raf. J Biol Chem 271:23512–23519, 1996
11. GRAVES JD, CAMPBELL JS, Krebs EG: Protein serine/threonine ki-
nases of the MAPK cascade. Ann N Y Acad Sci 766:320–343, 1995
12. SEGER R, KREBS EG: The MAPK signaling cascade. FASEB J 9:726–
735, 1995
13. SUN QY, BREITBART H, SCHATTEN H: Role of the MAPK cascade in
mammalian germ cells. Reprod Fertil Dev 11:443–450, 1999
14. MARSHALL CL: Specificity of receptor tyrosine kinase signaling:
Transient versus sustained extracellular signal-regulated kinase ac-
tivation. Cell 80:179–85, 1995
15. SEGER R, KREBS EG: The MAPK signaling cascade. FASEB J 9:726–
735, 1995
16. KARIN M: The regulation of AP-1 activity by mitogen-activated pro-
tein kinases. J Biol Chem 270:16483–16486, 1995
17. PAYNE DM, ROSSOMANDO AJ, MARTINO P, et al: Identification of the
regulatory phosphorylation sites in pp42/mitogen-activated protein
kinase (MAP kinase). EMBO J 10:885–892, 1991
18. GELLMAN DD, PIRANI CL, SOOTHILL JF, et al: Diabetic nephropathy:
A clinical and pathologic study based on renal biopsies. Medicine
(Baltimore) 38:312–367, 1959
19. NOMOTO Y, TOMINO Y, ENDOH M, et al: Modified open renal biopsy:
Results in 934 patients. Nephron 45:224–228, 1987
20. SUZUKI D, MIYAZAKI M, NAKA R, et al: In situ hybridization of in-
terleukin 6 in diabetic nephropathy. Diabetes 44:1233–1238, 1995
21. SUZUKI D, MIYAZAKI M, JINDE K, et al: In situ hybridization studies of
matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1
and type IV collagen in diabetic nephropathy. Kidney Int 52:111–
119, 1997
22. NISHIZUKA Y: The role of protein kinase C in cell surface signal
transduction and tumor promotion. Nature 308:693–698, 1984
23. NISHIZUKA Y: Studies and perspective of protein kinase C. Science
233:305–312, 1986
24. LYNCH JJ, FERRO TJ, BLUMENSTOCK FA, et al: Increased endothelial
albumin permeability mediated by protein kinase C activation. J
Clin Invest 85:1991–1998, 1990
25. RASMUSSEN H, FORDER J, KOJIMA I, et al: TPA-induced contraction
of isolated rabbit vascular smooth muscle. Biochem Biophys Res
Commun 122:776–784, 1984
26. KARIYA K, KAWAHARA Y, TSUDA T, et al: Possible involvement of
protein kinase C in platelet-derived growth factor-stimulated DNA
synthesis in vascular smooth muscle cells. Atherosclerosis 63:251–
255, 1987
27. HUHTALA P, CHOW LT, Tryggvason K: Structure of the human type
IV collagen gene. J Biol Chem 265:11077–11082, 1990
28. HACHIYA HL, TAKAYAMA S, WHITE MF, et al: Regulation of insulin
receptor internalization in vascular endothelial cells by insulin and
phorbol esters. J Biol Chem 262:6417–6424, 1987
29. PRESTA M, MAIER JAM, RAGNOTTI G: The mitogenic signaling path-
way but not plasminogen activator inducing pathway of basic fi-
broblast growth factor is mediated through protein kinase C in fetal
bovine aortic endothelial cells. J Cell Biol 109:1877–1884, 1989
30. ISHII H, KOYA D, KING GL: Protein kinase C activation and its role
in the development of vascular complications in diabetes mellitus.
J Mol Med 76:21–31, 1998
31. NISHIZUKA Y: Intracellular signaling by hydrolysis of phospholipids
and activation of protein kinase C. Science 258:607–614, 1992
32. KOYA D, JIROUSEK MR, LIN Y-W, et al: Characterization of pro-
tein kinase C b isoform activation on the gene expression of
1114 Toyoda et al: PKC-MAPK pathway mRNA expression in diabetic nephropathy
transforming growth factor-b , extracellular matrix components, and
prostanoids in the glomeruli of diabetic rats. J Clin Invest 100:115–
126, 1997
33. YAMAGUCHI K, OGITA K, NAKAMURA S, et al: The protein kinase C
isoforms leading to MAP-kinase activation in CHO cells. Biochem
Biophys Res Commun 210:639–647, 1995
34. TOMLINSON DR: Mitogen-activated protein kinases as glucose
transducers for diabetic complications. Diabetologia 42:1271–1281,
1999
35. INOKI K, HANEDA M, ISHIDA T, et al: Role of mitogen-activated pro-
tein kinases as downstream effectors of transforming growth factor-
b in mesangial cells. Kidney Int 58(Suppl 77):S76–S80, 2000
36. ISHII H, JIROUSEK MR, KOYA D, et al: Amelioration of vascular
dysfunctions in diabetic rats by an oral PKC b inhibitor. Science
272:728–731, 1996
37. KOYA D, HANEDA M, NAKAGAWA H, et al: Amelioration of accel-
erated diabetic mesangial expansion by treatment with a PKC b
inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
FASEB J 14:439–447, 2000
38. HOSHI S, NOMOTO K, KUROMITSU J, et al: High glucose induced VEGF
expression via PKC and ERK in glomerular podocytes. Biochem
Biophys Res Commun 290:177–184, 2002
39. ISONO M, CRUZ MC, CHEN S, et al: Extracellular signal-regulated ki-
nase mediates stimulation of TGF-beta1 and matrix by high glucose
in mesangial cells. J Am Soc Nephrol 11:2222–2230, 2000
40. LIU W, SCHOENKERMAN A, Lowe WL JR.: Activation of members
of the mitogen-activated protein kinase family by glucose in en-
dothelial cells. Am J Physiol Endocrinol Metab 279:E782–E790,
2000
41. NISHIDA E, GOTOH Y: The MAP kinase cascade is essential for di-
verse signal transduction pathways. Trends Biochem Sci 18:128–131,
1993
42. SHARMA K, ZIYADEH FN, ALZAHABI B, et al: Increased renal pro-
duction of transforming growth factor-b 1 in patients with type II
diabetes. Diabetes 46:854–859, 1997
43. SAKAI H, NAKA R, SUZUKI D, et al: In situ hybridization analysis of
TGF-b in glomeruli from patients with IgA nephropathy. Contrib
Nephrol 111:107–114, 1995
44. COHEN MP, SHARMA K, JIN Y, et al: Prevention of diabetic nephropa-
thy in db/db mice with glycated albumin antagonists: A novel treat-
ment strategy. J Clin Invest 95:2338–2345, 1995
45. MOGYOROSI A, ZIYADEH FN: Update on pathogenesis, markers, and
management of diabetic nephropathy. Curr Opin Nephrol Hyper-
tens 5:243–253, 1996
46. ZIYADEH FN: Mediators of hyperglycemia and the pathogenesis
of matrix accumulation in diabetic renal disease. Miner Electrolyte
Metab 21:292–302, 1995
47. WOLF G, ZIYADEH FN: Molecular mechanisms of diabetic renal hy-
pertrophy. Kidney Int 65:393–405, 1999
48. SHARMA K, ZIYADEH FN: Biochemical events and cytokine inter-
actions linking glucose metabolism to the development of diabetic
nephropathy. Semin Nephrol 17:80–92, 1997
49. DU X-L, EDELSTEIN D, ROSSETTI L, et al: Hyperglycemia-induced
mitochondrial superoxide overproduction activates the hexosamine
pathway and induces plasminogen activator inhibitor-1 expression
by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222–
12226, 2000
50. ZIYADEH FN, MOGYOROSI A, KALLURI R: Editorial review: Early
and advanced nonenzymatic glycation products in the pathogenesis
of diabetic kidney disease. Exp Nephrol 5:2–9, 1997
